Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMSNASDAQ:CYADNASDAQ:OBSV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/ACYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsOBSVObsEva$0.01$0.02$0.08▼$2.14$390K0.688.94 million shs50,231 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CYADCelyad Oncology0.00%0.00%0.00%0.00%-12.73%OBSVObsEva-60.00%-60.00%-75.00%-96.00%-97.62%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas PharmaceuticalsN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49CYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00OBSVObsEva$20.11M0.02N/AN/A$0.41 per share0.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/ACYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/A∞N/AN/A-416.36%-92.01%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17CYADCelyad OncologyN/AN/AN/AOBSVObsEvaN/A0.610.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%CYADCelyad OncologyN/AOBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%CYADCelyad Oncology0.94%OBSVObsEva14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionableCYAD, ADMS, and OBSV HeadlinesSourceHeadlineStockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)americanbankingnews.com - April 20 at 2:22 AMObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listinglobenewswire.com - April 3 at 1:00 AMObsEva Announces Update on Board of Directorsglobenewswire.com - March 19 at 2:00 AMObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023globenewswire.com - February 28 at 1:00 AMObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Datesbenzinga.com - February 26 at 12:34 AMObsEva SA OBSNmorningstar.com - November 11 at 10:37 PMObsEva SA OBSEFmorningstar.com - November 11 at 7:36 AMObsEva (NASDAQ: OBSV)fool.com - June 18 at 11:34 PMTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObservernews.google.com - May 10 at 1:37 AMObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Financenews.google.com - May 2 at 1:32 PMObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaqnews.google.com - May 2 at 8:31 AMObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswirenews.google.com - May 2 at 1:20 AMGameto Appoints Teri Loxam as Chief Financial Officer - citybiznews.google.com - April 28 at 11:20 PMObsEva Annual Report 2022 - Marketscreener.comnews.google.com - April 28 at 6:20 PMObsEva Annual Report 2022 - Yahoo Financenews.google.com - April 28 at 6:20 PMObsEva Annual Report 2022 - Benzinganews.google.com - April 28 at 1:20 PMObsEva Annual Report 2022 - EIN Newsnews.google.com - April 28 at 1:20 PMGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswirenews.google.com - April 28 at 8:19 AMEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journalnews.google.com - April 26 at 6:27 PMEndometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPRnews.google.com - April 23 at 8:45 PMObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.comnews.google.com - April 21 at 3:44 PMObsEva Announces Change of Central Securities Depositary - Yahoo Financenews.google.com - April 20 at 11:41 PMObsEva Announces Change of Central Securities Depositary - GlobeNewswirenews.google.com - April 20 at 1:10 AMTackling Reproductive Health and Fertility Care - Pharmaceutical Executivenews.google.com - April 13 at 6:41 PMNew MarketBeat Followers Over TimeCompany DescriptionsAdamas PharmaceuticalsNASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Celyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.